459 related articles for article (PubMed ID: 30046006)
21. CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells.
Yasutomi M; Christiaansen AF; Imai N; Martin-Orozco N; Forst CV; Chen G; Ueno H
Front Immunol; 2022; 13():840457. PubMed ID: 35273617
[TBL] [Abstract][Full Text] [Related]
22. Perturbed CD8
Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren HG; Sönnerborg A; Lund O; Reyes-Terán G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
Sci Rep; 2017 Jan; 7():40354. PubMed ID: 28084312
[TBL] [Abstract][Full Text] [Related]
23. TIGIT predominantly regulates the immune response via regulatory T cells.
Kurtulus S; Sakuishi K; Ngiow SF; Joller N; Tan DJ; Teng MW; Smyth MJ; Kuchroo VK; Anderson AC
J Clin Invest; 2015 Nov; 125(11):4053-62. PubMed ID: 26413872
[TBL] [Abstract][Full Text] [Related]
24. TIGIT enhances CD4
Chen F; Xu Y; Chen Y; Shan S
Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
[TBL] [Abstract][Full Text] [Related]
25. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
Chiang EY; Mellman I
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
[TBL] [Abstract][Full Text] [Related]
26. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
27. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Johnston RJ; Comps-Agrar L; Hackney J; Yu X; Huseni M; Yang Y; Park S; Javinal V; Chiu H; Irving B; Eaton DL; Grogan JL
Cancer Cell; 2014 Dec; 26(6):923-937. PubMed ID: 25465800
[TBL] [Abstract][Full Text] [Related]
28. Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals.
Yin X; Liu T; Wang Z; Ma M; Lei J; Zhang Z; Fu S; Fu Y; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
Front Immunol; 2018; 9():2341. PubMed ID: 30364127
[TBL] [Abstract][Full Text] [Related]
29. CD226 Attenuates Treg Proliferation via Akt and Erk Signaling in an EAE Model.
Wang N; Yi H; Fang L; Jin J; Ma Q; Shen Y; Li J; Liang S; Xiong J; Li Z; Zeng H; Jiang F; Jin B; Chen L
Front Immunol; 2020; 11():1883. PubMed ID: 32983109
[TBL] [Abstract][Full Text] [Related]
30. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
31. Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4
Yang M; Liu Y; Mo B; Xue Y; Ye C; Jiang Y; Bi X; Liu M; Wu Y; Wang J; Olsen N; Pan Y; Zheng SG
Cell Physiol Biochem; 2019; 52(5):1178-1192. PubMed ID: 30990587
[TBL] [Abstract][Full Text] [Related]
32. Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.
Ma B; Duan X; Zhou Q; Liu J; Yang X; Zhang D; Yang S; Du Y; Li H; Su C
J Cell Mol Med; 2019 Jul; 23(7):4514-4522. PubMed ID: 31090213
[TBL] [Abstract][Full Text] [Related]
33. Treg-Specific CD226 Deletion Reduces Diabetes Incidence in NOD Mice by Improving Regulatory T-Cell Stability.
Thirawatananond P; Brown ME; Sachs LK; Arnoletti JM; Yeh WI; Posgai AL; Shapiro MR; Chen YG; Brusko TM
Diabetes; 2023 Nov; 72(11):1629-1640. PubMed ID: 37625150
[TBL] [Abstract][Full Text] [Related]
34. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
[TBL] [Abstract][Full Text] [Related]
35. The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients.
Del Bello A; Gouin A; Chaubet C; Kamar N; Treiner E
Sci Rep; 2022 Jul; 12(1):11821. PubMed ID: 35821240
[TBL] [Abstract][Full Text] [Related]
36. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
37. CD226 identifies functional CD8
Huang H; Huang Z; Ge J; Yang J; Chen J; Xu B; Wu S; Zheng X; Chen L; Zhang X; Jiang J
Front Immunol; 2023; 14():1150803. PubMed ID: 37056782
[TBL] [Abstract][Full Text] [Related]
38. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
39. Competitive binding of CD226/TIGIT with poliovirus receptor regulates macrophage polarization and is involved in vascularized skin graft rejection.
Zhang D; Liu Y; Ma J; Xu Z; Duan C; Wang Y; Li X; Han J; Zhuang R
Am J Transplant; 2023 Jul; 23(7):920-934. PubMed ID: 37054890
[TBL] [Abstract][Full Text] [Related]
40. Higher TIGIT
Jin Z; Lan T; Zhao Y; Du J; Chen J; Lai J; Xu L; Chen S; Zhong X; Wu X; Li Y
Immunol Invest; 2022 Jan; 51(1):40-50. PubMed ID: 32819181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
